Filing Flows › Adma Biologics (ADMA) › Q2 2025
Adma Biologics (ADMA) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Adma Biologics (ADMA) reported revenue of $122M for the second quarter 2025 (Q2 2025), +14% from a year earlier and +6% from the quarter before. Operating margin was 35.1%, net earnings $34.2M (28.1% of revenue).
Adma Biologics, Q2 2025: revenue $122M (+14% year over year), operating margin 35.1%, net earnings $34.2M, operating cash flow $21.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $122M | +6% | +14% |
| Gross profit | $67.2M | +10% | +17% |
| Operating profit | $42.8M | +23% | +9% |
| Net earnings | $34.2M | +27% | +7% |
| Operating cash flow | $21.1M | — | -54% |
| Free cash flow | $18.7M | — | -57% |
What changed
Revenue was $122.0M in Q2 2025, up 14% year over year and up 6% from the previous quarter.
Gross margin was 55.1%, up 1.5 points from a year earlier. Operating profit was $42.8M, a 35.1% margin (down 1.5 points year over year). Of the extra revenue versus a year earlier, 24% reached operating profit, below the 37% margin then. Operating expenses grew 34% against revenue growth of 14%. The fastest-growing cost line was Research & development (+84%). Net earnings were $34.2M, up 7% year over year. The effective tax rate was 14.7%.
Operating cash flow was $21.1M (down 54% year over year), 62% of net earnings. Non-cash charges added back $2.0M of depreciation and amortization and $5.0M of share-based compensation. Working capital and other items used $20.0M. Capital expenditures of $2.4M left free cash flow of $18.7M.
Questions
What was Adma Biologics' revenue in the second quarter 2025?
Adma Biologics (ADMA) reported revenue of $122M for the second quarter 2025 (Q2 2025), +14% from a year earlier and +6% from the quarter before.
Was Adma Biologics profitable in the second quarter 2025?
Operating profit was $42.8M (35.1% of revenue) and net earnings $34.2M.
Source: Adma Biologics 10-Q on SEC EDGAR.